A new CB Insights report found that global digital health funding fell 36 percent in the first quarter of the year from that in Q4, 2021, with mental health and digital therapeutics suffering the greatest quarter-on-quarter decline.
We've made significant progress on interoperability from initiatives like the Trusted Exchange Framework and Common Agreement to health tech vendors and healthcare providers working to make patient data more accessible.
But is the interoperability glass half full or half empty? What progress have we made and what challenges remain?
This webinarsponsored by Surescripts will take stock of the past two years since the Covid-19 pandemic started and explore the progress we've made.
Bristol Myers Squibb and Nektar Therapeutics are ending a cancer drug research alliance after data showed the combination of their respective drugs failed clinical trials in kidney and bladder cancers. The disappointing results come one month after the drug combo failed a pivotal melanoma clinical trial.
New technologies for quantifying behavioral information and tracking neurological patterns have the potential to change treatment—but we must connect the data.
By Nancy M. Williams Thursday, April 14, 2022 1:27 PM
Some patients recognize no words at all 12 months after surgery, while others essentially have normal hearing in our analysis. This wide range of speech perception outcomes, we conclude, translates into considerable uncertainty for patients.
By Michael Schroeder Thursday, April 14, 2022 12:41 PM
Concord Health Partners and Columbia Pacific Advisors led the Series B funding round. The Austin, Texas-based company said it plans to use the money to grow clinical operations, and commercial and technology teams.
The U.S. government brought the suit against Methodist Le Bonheur Healthcare and Methodist Healthcare Memphis Hospitals, accusing the hospital system of paying millions of dollars of kickbacks to West Clinic, P.C., a cancer center with sites across the Southeast.
By Frank Vinluan Thursday, April 14, 2022 12:12 PM
Be Biopharma is developing cell therapies by engineering B cells to churn out therapeutic proteins with an initial focus on cancer and rare disease. The company's Series B financing comes as competitors in the space also make progress with their engineered B cell therapies.
Only 1 in 5 Americans use hearing aids because of the prohibitive costs — an average of $2,500 — so two senators are telling the FDA to stop dragging their feet to issue new regulations allowing over-the-counter hearing aids.
No comments